Cencora, a global pharmaceutical solutions organization, announced on April 28, 2025, its selection by Neurotech Pharmaceuticals, Inc. to provide integrated distribution and commercialization services. This partnership supports the U.S. launch of Neurotech's FDA-approved encapsulated cell therapy for idiopathic Macular Telangiectasia type 2 (MacTel).
Under the agreement, Cencora will serve as the exclusive specialty distributor and offer comprehensive commercialization support, including third-party logistics, specialty logistics, and patient support services. The company will leverage its Integration Hub solution to enhance visibility and streamline care coordination.
This collaboration highlights Cencora's leadership in specialty pharmaceutical distribution and its capabilities in the rapidly expanding cell and gene therapy market. The Alliance for Regenerative Medicine (ARM) estimates 7 to 14 additional CGT approvals in 2025, positioning Cencora to capitalize on this growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.